Skip to content
HowShorted

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2021

In 2021, BRAINSTORM CELL THERAPEUTICS INC.'s disclosed short interest ran from 15.22% of shares outstanding on 15 Jan 2021 to 3.78% on 31 Dec 2021, a change of -11.44 percentage points. The year's high was 15.22% on 15 Jan 2021 and its low 2.02% on 15 Nov 2021, averaging 7.45% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.22 days on 28 May 2021. Full history: BRAINSTORM CELL THERAPEUTICS INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for BRAINSTORM CELL THERAPEUTICS INC. in 2021

2021 in figures

Start of year
15.22% (15 Jan 2021)
End of year
3.78% (31 Dec 2021)
Change
-11.44 pp
High
15.22% (15 Jan 2021)
Low
2.02% (15 Nov 2021)
Average
7.45%
Highest days to cover
19.22 (28 May 2021)
SEC filings marked
7

Every report in 2021

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202115.22%10.62
29 Jan 202114.78%2.89
12 Feb 202111.82%3.3410-K filed, results (8-K)
26 Feb 202111.00%2.80
15 Mar 202111.81%5.60
31 Mar 202112.30%3.07
15 Apr 202110.27%11.20
30 Apr 202110.52%7.0810-Q filed, results (8-K)
14 May 202112.06%12.58
28 May 20219.82%19.22
15 Jun 20219.87%8.68
13 Aug 20212.87%4.3910-Q filed, results (8-K)
31 Aug 20212.87%9.21
15 Sep 20212.53%5.56
30 Sep 20212.70%10.18
15 Oct 20212.31%9.40
29 Oct 20212.05%5.11
15 Nov 20212.02%5.9910-Q filed
30 Nov 20212.57%1.62
15 Dec 20213.38%1.13
31 Dec 20213.78%3.11

See also: BRAINSTORM CELL THERAPEUTICS INC.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.